Working together to make a difference
During the recent Achema trade show, which took place in Frankfurt, Germany (11–15 June), GEA hosted a joint press conference with other key suppliers to the pharmaceutical sector to highlight a number of industry collaborations that are helping to facilitate the uptake of continuous manufacturing (CM) technology in the drug production sector.
Phil Gabb, Head of Solid Dosage Sales Support, GEA, said: “All the companies at the press conference have been actively collaborating with providers of complementary technologies and solutions. This is allowing us to deliver the services and infrastructure that our customers need to be able to implement continuous manufacturing.”
“There are several hurdles to negotiate when a company in the pharmaceutical industry decides to adopt continuous manufacturing. And whereas GEA can supply a wide range of process technology solutions, we don’t have the skills or capabilities in every service area to solve all the problems that might arise,” noted Gabb.
The key message, he added, is about companies working together to help the pharmaceutical industry overcome the different challenges involved in adopting continuous manufacturing. The companies involved included
“By collaborating with industry peers, we are all leading the way towards smaller, more flexible continuous processing technologies that have the potential to transform the future of pharmaceutical development and manufacturing — and deliver customised quantities of drugs to patients in need in a quick and efficient way,” commented Gabb.
“With ConsiGma, we certainly have a state-of-the-art CM solution and we’re committed to making science work, but we can’t do it all."
"This collaboration is all about a group of companies who are willing and able to co-operate in a particular area of business for the greater good of the pharmaceutical industry and, above all, the patient,” he concluded.